Prospective economic evaluation of phase III trial comparing irinotecan with infusional 5-FU in patients with advanced colorectal cancer

被引：0
|
作者：
Schmitt, C
Jolain, B
Van Cutsem, E
机构：
[1] UZ Gasthuisberg, Leuwen, Belgium
[2] Rhone Poulenc Rorer, Antony, France
[3] ARCOS, Issy Les Moulineaux, France
来源：
MEDICAL DECISION MAKING | 1998年 / 18卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：484 / 484
页数：1
相关论文
共 50 条
  • [1] Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer: after 5-FU failure
    Schmitt, C
    Blijham, G
    Jolain, B
    Rougier, P
    Van Cutsem, E
    ANTI-CANCER DRUGS, 1999, 10 (06) : 617 - 623
  • [2] Phase I trial of cisplatin, infusional 5-FU and irinotecan in advanced gastric cancer.
    Seguru, A
    Fernández-Martos, C
    Aparicio, J
    Campos, JM
    Vicent, J
    Busquier, I
    Molins, C
    Guillem, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 156S - 156S
  • [3] Phase II trial of irinotecan (CPT-11) in patients with 5-FU resistant advanced colorectal cancer
    Vicent, JM
    Aparicio, J
    Lizon, J
    Molins, C
    Alonso, JD
    Gimenez-Arnau, JM
    Camps, C
    Segura, A
    Rizo, A
    Xarles, J
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 45
  • [4] Cost-effectiveness analysis of irinotecan compared with best estimated infusional 5-FU regimen in patients with advanced colorectal cancer
    Neymark, N
    Adriaenssen, I
    Schmitt, C
    MEDICAL DECISION MAKING, 1998, 18 (04) : 461 - 461
  • [5] Combination therapy with infusional 5-FU and 'Tomudex' for patients (pts) with advanced colorectal cancer - A phase I study
    Harstrick, A
    Mayer, S
    Hilger, R
    Muller, C
    Dohmen, D
    Kloppel, R
    Vanhoefer, U
    Scheulen, ME
    Wilke, H
    Seeber, S
    ANNALS OF ONCOLOGY, 1998, 9 : 35 - 36
  • [6] A phase II trial of gefitinib in combination with 5-FU/LV/irinotecan in patients with colorectal cancer.
    Redlinger, M
    Kramer, A
    Flaherty, K
    Sun, W
    Haller, D
    O'Dwyer, PJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 310S - 310S
  • [7] Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
    A Madi
    D Fisher
    R H Wilson
    R A Adams
    A M Meade
    S L Kenny
    L L Nichols
    M T Seymour
    H Wasan
    R Kaplan
    T S Maughan
    British Journal of Cancer, 2012, 107 : 1037 - 1043
  • [8] Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
    Madi, A.
    Fisher, D.
    Wilson, R. H.
    Adams, R. A.
    Meade, A. M.
    Kenny, S. L.
    Nichols, L. L.
    Seymour, M. T.
    Wasan, H.
    Kaplan, R.
    Maughan, T. S.
    BRITISH JOURNAL OF CANCER, 2012, 107 (07) : 1037 - 1043
  • [9] Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents
    Schmoll, HJ
    EUROPEAN JOURNAL OF CANCER, 1996, 32A : S18 - S22
  • [10] Randomized phase III trial comparing infused irinotecan 5-fluorouracil (5-FU) folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3)
    Van Cutsem, E
    Labianca, R
    Hossfeld, D
    Bodoky, G
    Roth, A
    Aranda, E
    Nordlinger, B
    Assadourian, S
    Wang, K
    Cunningham, D
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1090S - 1090S
12345